Pasithea Therapeutics (NASDAQ:KTTA) Releases Earnings Results

Pasithea Therapeutics (NASDAQ:KTTA) announced its quarterly earnings data on Monday. The company reported ($2.41) earnings per share (EPS) for the quarter, Zacks reports.

Pasithea Therapeutics Stock Performance

Shares of Pasithea Therapeutics stock traded up $0.01 on Monday, reaching $1.25. 61,129 shares of the stock were exchanged, compared to its average volume of 535,974. The firm’s 50 day moving average is $1.70 and its 200-day moving average is $2.97. Pasithea Therapeutics has a one year low of $0.92 and a one year high of $9.25.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.